scholarly journals NRAS mutation status is an independent prognostic factor in metastatic melanoma

Cancer ◽  
2011 ◽  
Vol 118 (16) ◽  
pp. 4014-4023 ◽  
Author(s):  
John A. Jakob ◽  
Roland L. Bassett ◽  
Chaan S. Ng ◽  
Jonathan L. Curry ◽  
Richard W. Joseph ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Metastatic Melanoma ◽  
Independent Prognostic Factor ◽  
Nras Mutation ◽  
Mutation Status

scholarly journals TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma

2014 ◽  
Vol 106 (9) ◽  
Author(s):  
Klaus G. Griewank ◽  
Rajmohan Murali ◽  
Joan Anton Puig-Butille ◽  
Bastian Schilling ◽  
Elisabeth Livingstone ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cutaneous Melanoma ◽  
Independent Prognostic Factor ◽  
Tert Promoter Mutation ◽  
Promoter Mutation ◽  
Mutation Status ◽  
Tert Promoter

Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 9070-9070 ◽  
Author(s):  
Paola Queirolo ◽  
Francesco Spagnolo ◽  
Maresa Altomonte ◽  
Vanna Chiarion-Sileni ◽  
Jacopo Pigozzo ◽  
...  
Keyword(s):  
Adverse Events ◽  
Disease Control ◽  
Metastatic Melanoma ◽  
Therapeutic Option ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Wild Type ◽  
Nras Mutation ◽  
Mutation Status

9070 Background: Ipilimumab was the first agent approved for the treatment of unresectable or metastatic melanoma to show a survival benefit in randomised phase III trials. Efficacy and safety of ipilimumab treatment outside of clinical trials and the correlation with BRAF and NRAS mutation status were evaluated. Methods: Ipilimumab was available upon physician request for patients (pts) aged ≥16 years with unresectable stage III/stage IV melanoma who had either failed systemic therapy or were intolerant to ≥1 systemic treatment and for whom no other therapeutic option was available. Ipilimumab 3 mg/kg was administered intravenously every 3 weeks for 4 doses. Tumour assessments were conducted at baseline and after completion of induction therapy using immune-related response criteria. BRAF and NRAS mutation status was retrospectively collected for all available pts. Patients were monitored for adverse events, including immune-related AEs, using Common Terminology Criteria for Adverse Events v.3.0. Results: In total, 855 Italian pts participated in the EAP from June 2010 to January 2012 across 55 centres. With a median follow-up of 6.5 months (range 0.5-30), the disease control rate among 833 pts evaluable for response was 34.3%: 28 pts (3.4%) with complete response, 83 (10.0%) with partial response and 175 (20.9%) with stable disease. As of December 2012, median progression-free survival and overall survival were 3.3 months and 7.2 months respectively, with 1-year survival rate of 36%. The Table shows mutation status for available patients. Disease control rates were comparable among pts with BRAF positive tumors and BRAF wild-type (37.5% vs 39.5%) and among pts with NRAS positive tumors and NRAS wild-type (57.1% vs 49.3%). Survival curves were also comparable between groups. 399 pts (46.7%) had a AEs of any grade, with 286 (33.5%) considered IrAEs. IrAEs were reversible with protocol specific guidelines. Conclusions: Based on EAP data, ipilimumab is an effective and safe treatment for pretreated pts with metastatic melanoma regardless BRAF and NRAS mutation status. [Table: see text]

scholarly journals Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

2014 ◽  
Vol 111 (2) ◽  
pp. 292-299 ◽  
Author(s):  
M S Carlino ◽  
L E Haydu ◽  
H Kakavand ◽  
A M Menzies ◽  
A L Hamilton ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Distant Metastasis ◽  
Nras Mutation ◽  
Mutation Status ◽  
Response To Chemotherapy

Soluble Syndecan-1 (sCD138) Is an Independent Prognostic Factor in Patients with Chronic Lymphocytic Leukemia.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 713-713
Author(s):  
I. Jilani ◽  
M. Keating ◽  
W. William ◽  
A. Ferrajoli ◽  
H. Kantarjian ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Chronic Lymphocytic Leukemia ◽  
White Cell Count ◽  
Continuous Variable ◽  
Independent Prognostic Factor ◽  
Lymphocytic Leukemia ◽  
Soluble Form ◽  
Mutation Status ◽  
Previously Treated

Abstract Syndecan-1 (sCD138) is a transmembrane heparan sulfate-bearing proteoglycan expressed in epithelial cells as well as hematopoitic cells that demonstrate plasmacytioid differentiation. CD138 is believed to play a role in cell-cell and cel-matrix interaction. A soluble form of CD138 (sCD138) has been reported to be elevated in multiple myeloma. Higher levels of sCD138 have been reported to correlate with poor outcome in myeloma. While some cells in patients with chronic lymphocytic leukemia (CLL) can demonstrate plasmacytoid differentiation, CD138 is usually not expressed in B-cell CLL. We investigated the levels of circulating sCD138 in the plasma of 104 patients with CLL and correlated these levels with clinical behavior. sCD138 levels were elevated in patients with CLL as compared with normal control subjects (median, 52.8, range: 13.4-252.7 ng/mL) (P<0.01). Patients with levels of sCD138 higher than the median (53 ng/mL) had significantly shorter survival (Figure; P=0.0002). More importantly, this association was independent of both the IgVH mutation status and beta2- microglobulin levels. The same was true whether patients were previously treated (40 patients, P=0.004) or not (64 patients, P=0.01). Patients who had mutated IgVH but high sCD138 levels (>53 ng/mL) had significantly shorter survival than those with mutated IgVH and lower levels of sCD138. Similarly, patients with unmutated IgVH but high levels of sCD138 (>53 ng/mL) had significantly shorter survival than those with lower levels of sCD138 and unmutated IgVH (P=0.007). When CLL patients were dichotomized into 2 groups according to the median level of sCD138, there was significant positive correlation with age, platelet count, male sex, white cell count, and sCD23 level (all P<0.05). In contrast, no significant correlation with these prognostic factors or survival was found when sCD138 was considered as a continuous variable. This suggests that the role of sCD138 is more related to its presence or absence. The data presented here suggest that sCD138 is a powerful independent prognostic factor in CLL, and further studies are needed to explore its biological role and the potential of targeting this pathway as a therapeutic approach. Figure Figure

scholarly journals Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma

Cancer ◽  
2006 ◽  
Vol 106 (5) ◽  
pp. 1130-1139 ◽  
Author(s):  
Henrik Schmidt ◽  
Julia Sidenius Johansen ◽  
Julie Gehl ◽  
Poul F. Geertsen ◽  
Kirsten Fode ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Serum Level ◽  
Metastatic Melanoma ◽  
Elevated Serum ◽  
Independent Prognostic Factor ◽  
Poor Survival ◽  
Elevated Serum Level

Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 3015-3015 ◽  
Author(s):  
Richard Wayne Joseph ◽  
Jeroen Elassaiss-Schaap ◽  
Jedd D. Wolchok ◽  
Anthony M. Joshua ◽  
Antoni Ribas ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Overall Survival ◽  
Prognostic Factor ◽  
Metastatic Melanoma ◽  
Tumor Size ◽  
Independent Prognostic Factor

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy

2014 ◽  
Vol 50 (15) ◽  
pp. 2668-2676 ◽  
Author(s):  
Andrew P. Barbour ◽  
Yue Hang Tang ◽  
Nicola Armour ◽  
Ken Dutton-Regester ◽  
Lutz Krause ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Adjuvant Therapy ◽  
Braf Mutation ◽  
Independent Prognostic Factor ◽  
Stage Iiib ◽  
Mutation Status ◽  
Resected Stage
Sign in / Sign up

Export Citation Format

Share Document